Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.

Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL.

J Psychopharmacol. 2020 Feb;34(2):167-180. doi: 10.1177/0269881119895520. Epub 2020 Jan 16.

PMID:
31941394
2.

From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner.

Kettner H, Gandy S, Haijen ECHM, Carhart-Harris RL.

Int J Environ Res Public Health. 2019 Dec 16;16(24). pii: E5147. doi: 10.3390/ijerph16245147.

3.

Decreased directed functional connectivity in the psychedelic state.

Barnett L, Muthukumaraswamy SD, Carhart-Harris RL, Seth AK.

Neuroimage. 2019 Dec 17;209:116462. doi: 10.1016/j.neuroimage.2019.116462. [Epub ahead of print]

4.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.

Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S.

Psychopharmacology (Berl). 2019 Dec 18. doi: 10.1007/s00213-019-05417-7. [Epub ahead of print]

PMID:
31853557
5.

Neural correlates of the DMT experience assessed with multivariate EEG.

Timmermann C, Roseman L, Schartner M, Milliere R, Williams LTJ, Erritzoe D, Muthukumaraswamy S, Ashton M, Bendrioua A, Kaur O, Turton S, Nour MM, Day CM, Leech R, Nutt DJ, Carhart-Harris RL.

Sci Rep. 2019 Nov 19;9(1):16324. doi: 10.1038/s41598-019-51974-4.

6.

Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.

Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, Nutt DJ, Deco G, Carhart-Harris RL, Kringelbach ML, Cabral J.

Neuroimage. 2019 Oct 1;199:127-142. doi: 10.1016/j.neuroimage.2019.05.060. Epub 2019 May 25.

PMID:
31132450
7.

Psychedelics as a treatment for disorders of consciousness.

Scott G, Carhart-Harris RL.

Neurosci Conscious. 2019 Apr 21;2019(1):niz003. doi: 10.1093/nc/niz003. eCollection 2019.

8.

Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition.

Atasoy S, Vohryzek J, Deco G, Carhart-Harris RL, Kringelbach ML.

Prog Brain Res. 2018;242:97-120. doi: 10.1016/bs.pbr.2018.08.009. Epub 2018 Oct 25. Review.

PMID:
30471684
9.

Predicting Responses to Psychedelics: A Prospective Study.

Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, Nutt D, Daws RE, Hampshire ADG, Lorenz R, Carhart-Harris RL.

Front Pharmacol. 2018 Nov 2;9:897. doi: 10.3389/fphar.2018.00897. eCollection 2018.

10.

How do psychedelics work?

Carhart-Harris RL.

Curr Opin Psychiatry. 2019 Jan;32(1):16-21. doi: 10.1097/YCO.0000000000000467. Review.

PMID:
30394903
11.

Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD.

Deco G, Cruzat J, Cabral J, Knudsen GM, Carhart-Harris RL, Whybrow PC, Logothetis NK, Kringelbach ML.

Curr Biol. 2018 Oct 8;28(19):3065-3074.e6. doi: 10.1016/j.cub.2018.07.083. Epub 2018 Sep 27.

12.

Psychedelics, Meditation, and Self-Consciousness.

Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A.

Front Psychol. 2018 Sep 4;9:1475. doi: 10.3389/fpsyg.2018.01475. eCollection 2018.

13.

Serotonin, psychedelics and psychiatry.

Carhart-Harris RL.

World Psychiatry. 2018 Oct;17(3):358-359. doi: 10.1002/wps.20555. No abstract available.

14.

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.

Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, Mehta MA.

Sci Rep. 2018 May 29;8(1):8236. doi: 10.1038/s41598-018-26656-2.

15.

The entropic brain - revisited.

Carhart-Harris RL.

Neuropharmacology. 2018 Nov;142:167-178. doi: 10.1016/j.neuropharm.2018.03.010. Epub 2018 Mar 14. Review.

PMID:
29548884
16.

Psychedelics and the essential importance of context.

Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M.

J Psychopharmacol. 2018 Jul;32(7):725-731. doi: 10.1177/0269881118754710. Epub 2018 Feb 15.

PMID:
29446697
17.

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

Carrillo F, Sigman M, Fernández Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, Carhart-Harris RL.

J Affect Disord. 2018 Apr 1;230:84-86. doi: 10.1016/j.jad.2018.01.006.

PMID:
29407543
18.

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Roseman L, Nutt DJ, Carhart-Harris RL.

Front Pharmacol. 2018 Jan 17;8:974. doi: 10.3389/fphar.2017.00974. eCollection 2017.

19.

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.

Lyons T, Carhart-Harris RL.

J Psychopharmacol. 2018 Jul;32(7):811-819. doi: 10.1177/0269881117748902. Epub 2018 Jan 17.

20.

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.

Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL.

Neuropharmacology. 2018 Nov;142:263-269. doi: 10.1016/j.neuropharm.2017.12.041. Epub 2017 Dec 27.

Supplemental Content

Loading ...
Support Center